Press Releases
Pfizer Announces FDA Advisory Committees Recommend ALO-02 Extended-Release Capsules For Approval
Pfizer Inc. announced that the U.S. FDA Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor of approval of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride). ...
Press Releases
ALF 5000: New Filling and Closing Machine for Ampoules and Injection Bottles from Bosch
Increased performance and higher safety Output of up to 600 containers per minute Flexible use: compatible with all commonfilling systems Optional100% in-process control Bosch Packaging Technology, a...
Press Releases
AstraZeneca,Ironwood enter U.S. licensing agreement for lesinurad
AstraZeneca announced that it has completed the licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol. Zurampic is approved in the US, in combination...
Press Releases
Shire Plc completes combination with Baxalta Inc creating global biotech leader in rare diseases
Shire plc completed its previously announced combination with Baxalta Incorporated ,creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. Through the combination, Shire expects to deliver double-digit...
Press Releases
Mylan NV launches generic version of Celgenes Vidaza injection
Mylan N.V. announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for...
Press Releases
Peregrine Pharmaceuticals Updates Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months ...
Press Releases
EU approves Novartis drug Afinitor to treat certain types of advanced GI and lung NET
Novartis announced that the EU has approved Afinitor®(everolimus) tablets for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.